Biotechnology

Oragenics

Oragenics released FY2025 9 Months Earnings on November 7 (EST), actual revenue USD 0, actual EPS USD -8.7207

Oragenics released FY2025 Q3 earnings on November 7 (EST), actual revenue USD 0, actual EPS USD -1.9646

Oragenics Collaborates with Receptor.AI to Accelerate Drug Development

Oragenics released FY2025 Q2 earnings on August 8 (EST) with actual revenue of USD 0 and EPS of USD -3.1046

Oragenics released FY2025 Semi-Annual earnings on August 8 (EST) with actual revenue of USD 0 and EPS of USD -6.6229

Oragenics Signs Manufacturing Agreement with Sterling

Oragenics Announces Offering of Convertible Preferred Stock to Raise Funds

Odyssey Health Disposes of Oragenics Inc. Shares

Oragenics Submits Beneficial Ownership Statement with Odyssey Health Holding 10%

Wall Street Zen Analysts Assigns Oragenics a Sell Rating

Oragenics released FY2025 Q1 earnings on May 9, 2025 (EST) with actual revenue of USD 0 and EPS of USD -3.6514

Oragenics, Inc. Submits Clinical Trial Protocol for Review

Oragenics Inc Submits Application to Health and Disability Ethics Committee for Phase II Concussion Trial

Oragenics released FY2024 annual earnings on March 14 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -47.88 (forecast USD 360.04)

Oragenics released FY2024 Q4 earnings on March 14 (EST) with actual revenue of USD 0 and EPS of USD -8.4325

Oragenics released FY2024 Q3 earnings on November 13 (EST), actual revenue USD 0, actual EPS USD -11.3182

Oragenics released FY2024 9 Months Earnings on November 13 (EST) with actual revenue of USD 0 and EPS of USD -47.6209

Oragenics Inc. Public Offering Pricing

Oragenics Inc. has successfully completed the formulation and filling of its nasal spray drug ONP-002 and is preparing for Phase II clinical trials.

Oragenics plans to start Phase 2 human trials of ONP-002 in Q4 2023

Intelligent Bio Solutions

Anghami

UTime

ESH ACQUISITION CORP COM USD0.0001 CL A (S/R 13/06/2028)

Northann

FG MERGER II CORP COM USD0.0001 11/02/2030 (SUBS/RTS)

ESH Acquisition

INFLECTION POINT ACQUISITION CORP V COM USD0.0001 CL A (SUB/RIGHST)

RISING DRAGON ACQUISITION CORP COM USD0.0001 15/11/2028 (SUBS/RT)

Datavault AI

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap

Oragenics(OGEN.US)